TAM
EIGR

Tiverton Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Tiverton Asset Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-31
Closed -$10K – 668
2018
Q4 		$10K Buy
+31
New +$10K ﹤0.01% 490

Other funds holding EIGR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tiverton Asset Management's EIGR Position: Q1 2019 in Review

Tiverton Asset Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2019, closing a stake of 31 shares — an estimated $10K sold.

Tiverton Asset Management first reported a position in EIGR in Q4 2018 and held it in 1 quarter. The position peaked at $10K in Q4 2018. 63 funds tracked by Wall St. Rank hold EIGR as of Q1 2019.

  • Tiverton Asset Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Tiverton Asset Management sold 31 Eiger BioPharmaceuticals, Inc. shares in Q1 2019, an estimated $10K.
  • Tiverton Asset Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • Tiverton Asset Management's Eiger BioPharmaceuticals, Inc. position peaked at $10K in Q4 2018.
  • 63 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2019.

Based on Tiverton Asset Management's 13F filing for Q1 2019, filed 13 May 2019.